Key result
Undertreatment with class I therapies is linked to ~187% higher six-month mortality in NSTEACS patients.
Why the study?
Class I recommended treatments were underused in high-risk patients with NSTEACS, and the impact of this undertreatment on outcomes was unclear.
Does undertreatment with class I recommended therapies increase mortality in high-risk patients with NSTEACS?
Cohort (n=1,877)
Yes
Does undertreatment with class I recommended therapies increase mortality in high-risk patients with NSTEACS?
Odds Ratio: 2.87 (95% CI 1.27–6.52)
p-value: p=0.012
Undertreatment with class I recommended therapies is common in high-risk NSTEACS patients and independently predicts increased six-month mortality.
May warrant closer monitoring of guideline adherence in NSTEACS; leaves open whether closing therapy gaps improves survival.
OBJECTIVE: To analyse intensity of treatment of high-risk patients with non-ST elevation acute coronary syndromes (NSTEACS) included in the DESCARTES (Descripción del Estado de los Sindromes Coronarios Agudos en un Registro Temporal Español) registry. PATIENTS AND SETTING: Patients with NSTEACS (n = 1877) admitted to 45 randomly selected Spanish hospitals in April and May 2002 were studied. DESIGN: Patients with ST segment depression and troponin rise were considered high risk (n = 478) and were compared with non-high risk patients (n = 1399). RESULTS: 46.9% of high-risk patients versus 39.5% of non-high-risk patients underwent angiography (p = 0.005), 23.2% versus 18.8% (p = 0.038) underwent percutaneous revascularisation, and 24.9% versus 7.4% (p < 0.001) were given glycoprotein IIb/IIIa inhibitor. In-hospital and six-month mortality were 7.5% versus 1.1% and 17% versus 4.6% (p < 0.001), respectively. A treatment score (> or = 4, 2-3 and < 2) was defined according to the number of class I interventions recommended in clinical guidelines: aspirin, clopidogrel, beta blockers, angiotensin-converting enzyme inhibitors, statins and revascularisation. Independent predictors of six-month mortality were age (odds ratio (OR) 1.07, 95% confidence interval (CI) 1.04 to 1.10, p < 0.001), diabetes (OR 1.92, 95% CI 1.14 to 3.22, p = 0.014), previous cardiovascular disease (OR 4.17, 95% CI 1.63 to 10.68, p = 0.003), high risk (OR 2.20, 95% CI 1.30 to 3.71, p = 0.003) and treatment score < 2 versus > or = 4 (OR 2.87, 95% CI 1.27 to 6.52, p = 0.012). CONCLUSIONS: Class I recommended treatments were underused in high-risk patients in the DESCARTES registry. This undertreatment was an independent predictor of death of patients with an acute coronary syndrome.
No takes yet. Share an insight, caveat, or question.
Heras et al. (2006) conducted a cohort in Non-ST segment elevation acute coronary syndromes (NSTEACS) (n=1,877). Undertreatment (treatment score < 2) vs. Guideline-directed treatment (score ≥ 4) was evaluated on Six-month mortality (OR 2.87, 95% CI 1.27 to 6.52, p=0.012). Undertreatment with class I recommended therapies (score < 2 vs ≥ 4) was an independent predictor of six-month mortality in NSTEACS patients (OR 2.87; 95% CI 1.27-6.52; p=0.012).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: